en · de · es
semax-notes.peptides6155.com › Blog › Semax Background And Mechanism — Worked Examples

Semax Background And Mechanism — Worked Examples

By Editorial Desk · published 2026-07-13 · last reviewed 2026-08-01 · Blog

Neurotrophic signalling is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Background And Mechanism

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

Background and Development History

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SCalculated for the free peptide
Molar mass813.9 g/molAnhydrous free base
Peptide classSynthetic heptapeptideACTH(4-10) analogue
Parent fragmentACTH(4-10)Adrenocorticotropic hormone segment
Developmental originInstitute of Molecular Genetics, MoscowWork began in the 1980s

Semax Background and Molecular Structure

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.

Related pages on this site

Semax Peptide Background and Identity

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Further detail

Administration: Administers the Secretariat as well as looks after personal matters of the Chairman/Members and other Officers/Staff of the commission. All India Services: Recruitment to All India Services is done either by direct recruitment, through Civil Services Examination or by promotion from the State Service. The AIS Branch handles the promotions of State Service officers to the IAS, IPS and IFS. It also handles policy matters relating to All India Services and amendments in the 'Promotion Regulations' of respective services. Appointments: It carries out appointments to central services based on Promotion (based on proposals from various Ministries/Departments/Union Territories and from certain local bodies) and by the means of Deputation and Absorption. Examinations: It carries out merit-based selection and recommendation of candidates through various examinations such as the Engineering Services Examination, Combined Medical Services Examination, Defence Services Examination, Civil Services Examination, etc., to Group A and Group B Services of the Government of India. General: Primarily deals with day-to-day housekeeping work for the Commission, such as arrangements and facilitation for the conduct of Examinations by the UPSC, printing the Annual Report, etc.

== Literature == Schaefer, T. (1962). "The Proton Magnetic Resonance Spectrum of 1-Fluoro-2,4-Dinitrobenzene". Canadian Journal of Chemistry. 40 (3): 431–433. doi:10.1139/v62-068. Nageswara Rao, B.D. (1964). "The1H and19F resonance spectra of 1-fluoro-2,4-dinitrobenzene". Molecular Physics. 7 (4): 307–310. Bibcode:1964MolPh...7..307N. doi:10.1080/00268976300101071. Wilkins, A.; Small, R. W. H. (1991). "Structure of 1-fluoro-2,4-dinitrobenzene". Acta Crystallographica Section C. 47 (1): 220–221. Bibcode:1991AcCrC..47..220W. doi:10.1107/S0108270190007326.

== Further reading == Carbone, Christine E.; Loveland, Anna B.; Gamper, Howard B.; Hou, Ya-Ming; Demo, Gabriel; Korostelev, Andrei A. (December 2021). "Time-resolved cryo-EM visualizes ribosomal translocation with EF-G and GTP". Nature Communications. 12 (1): 7236. doi:10.1038/s41467-021-27415-0. PMC 8668904.

Many of these will stealthily snatch small cubs right from under the sleeping mother. There is record of a golden eagle snatching a yearling cub. Once out of hibernation, mother bears may be able to fight off most potential predators. Even cougars will be displaced by an angry mother bear if they are discovered stalking the cubs. Flooding of dens after birth may also occasionally kill newborn cubs. Bear fatalities are mainly attributable to human activities. Seasonally, thousands of black bears are hunted legally across North America, and some are illegally poached or trapped unregulated. Auto collisions also may kill many black bears annually.

killed virus ("non-infectious") adjuvanted killed virus non adjuvanted modified-live virus (MLV or "infectious") adjuvanted modified-live virus non adjuvanted Combination vaccines that protect against several common viruses, including FPLV, are also available. Selection or use of a specific type/brand of a vaccine may vary depending on the overall risk of viral infection to the specific animal in its environment, along with considerations for the time it takes to confer protection, its overall efficacy, the animal's health, and the potential risks associated with MLV vs killed, adjuvanted vs nonadjuvanted, intranasal/ocular vs injection. Modified-live FPLV vaccines are not recommended in pregnant queens, very young kittens, or cats with FIV or FeLV. Kittens without maternally derived antibodies are especially vulnerable. FPLV vaccination can start as early as 4 weeks of age for kittens at high risk but are usually started at 6 weeks, then given every 3–4 weeks until 16 weeks of age. For cats older than 16 weeks, 2 doses, 3 to 4 weeks apart is generally recommended, followed by a 6-month to 1-year booster. Thereafter, a booster vaccination every 3 years is usually recommended; a blood titer test can be done to determine individual antibody levels for catering the timing of boosters.

Sources: en.wikipedia.org

Background from the literature

=== As livestock feed === Mealworm has been investigated as a potential ingredient in livestock feed due to its high protein content and balanced amino acid profile, making it nutritionally suitable as a substitute for conventional protein sources such as fish meal or soybean meal. Although they can be raised in small spaces suitable for industrial production, life cycle assessment studies have shown that mealworm protein performs worse than soybean or fish meal protein in terms of energy use, greenhouse gas emissions, acidification and eutrophication.

== Covalent perchlorates == Although typically found as a non-coordinating anion, a few metal complexes are known. Hexaperchloratoaluminate and tetraperchloratoaluminate are strong oxidising agents. Several perchlorate esters are known. For example, methyl perchlorate is a high energy material that is a strong alkylating agent. Chlorine perchlorate is a covalent inorganic analog.

== Early life and education == Daniel Roy Gilchrist Noboa Azín was born in Miami, Florida, United States on 30 November 1987, and was raised in Guayaquil. He is the son of Ecuadorian businessman Álvaro Noboa and Ecuadorian physician Annabella Azín. Noboa graduated from the New York University Stern School of Business in 2010, and later earned a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois. He studied at Harvard University in 2020. In 2022, he obtained a master's degree in political communication and strategic governance from George Washington University under the supervision of professor Roberto Izurieta, Noboa's former press secretary.

Skin care or skincare is the practice and process of maintaining and improving the health and appearance of the skin. It includes washing, moisturizing, protecting from the sun, and treating skin problems like acne and dryness. Facial care is skin care for the face. Skin care is at the interface of cosmetics and dermatology. Skin care differs from dermatology by its inclusion of non-physician professionals, such as estheticians and nursing staff. Skin care includes modifications of individual behavior and of environmental and working conditions. Skin care is applied during recovery from wound healing, radiation therapy, and the management of some medications. Skin care needs vary according to age, diseases, wounds, exposure to the sun, environmental extremes, and chemicals. Skin care products exist as regulated prescription drugs and as topical agents marketed as cosmetics but having no clinical proof of efficacy. A skin care physician is called a dermatologist.

Sources: en.wikipedia.org

Frequently asked questions

What is semax derived from?

Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.

Is semax approved as a medicine?

It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.

Why is much of the research published in Russian?

The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.

In which form is semax typically supplied?

Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.

Network